Grant: Alliance Grants
McMaster University
$50,000.00
Diagnostics for post-COVID-19 lung fibrosis_x000d_
FY 2020-21
Summary
The global transmission of SARS-CoV-2 has imposed numerous healthcare delivery challenges in multiple jurisdictions around the world, independent of socio-economic status of the region. In Canada, there are 87,482 confirmed cases and 6760 deaths as of 27th of May 2020. Acute respiratory distress syndrome (ARDS) is the main cause of death for COVID-19 patients. The end result of ARDS is pulmonary oedema, reduced ventilation capacity, lung damage, and impaired gas exchange leading to severe COVID-19 disease and poor health outcomes. The main cause of ARDS is the cytokine storm, in which an excessive level of cytokines and chemokines are released due to an uncontrolled immune responses. The importance of IL-6 in COVID-19 related ARDS is highlighted by the global clinical trials using anti-IL-6 medications (tocilizumab) and the central role that elevated IL-6 protein plays in development and progression of lung fibrosis.
The goal of our partnership is to combine academic and industry expertise in fibrotic lung disease, the role of IL-6 in this process, and diagnostics, to enable rapid point-of-need detection of IL-6 in COVID-19 patients for pro-active detection of ARDS.
The outcomes and impacts of our partnership will be a fully-integrated diagnostic system the size of a toaster for bedside use, able to identify which patients will develop ARDS and require aggressive pro-active interventions to minimize morbidity and mortality associated with COVID-19-induced lung damage.
Program
Alliance Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
555255-2020
Name nom
Hirota, Jeremy
Department département
Medicine
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Diagnostics for post-COVID-19 lung fibrosis_x000d_
Keyword
NSERC
Application summary
The global transmission of SARS-CoV-2 has imposed numerous healthcare delivery challenges in multiple jurisdictions around the world, independent of socio-economic status of the region. In Canada, there are 87,482 confirmed cases and 6760 deaths as of 27th of May 2020. Acute respiratory distress syndrome (ARDS) is the main cause of death for COVID-19 patients. The end result of ARDS is pulmonary oedema, reduced ventilation capacity, lung damage, and impaired gas exchange leading to severe COVID-19 disease and poor health outcomes. The main cause of ARDS is the cytokine storm, in which an excessive level of cytokines and chemokines are released due to an uncontrolled immune responses. The importance of IL-6 in COVID-19 related ARDS is highlighted by the global clinical trials using anti-IL-6 medications (tocilizumab) and the central role that elevated IL-6 protein plays in development and progression of lung fibrosis.
The goal of our partnership is to combine academic and industry expertise in fibrotic lung disease, the role of IL-6 in this process, and diagnostics, to enable rapid point-of-need detection of IL-6 in COVID-19 patients for pro-active detection of ARDS.
The outcomes and impacts of our partnership will be a fully-integrated diagnostic system the size of a toaster for bedside use, able to identify which patients will develop ARDS and require aggressive pro-active interventions to minimize morbidity and mortality associated with COVID-19-induced lung damage.